©
Cyrus Mower
T1D is an autoimmune condition where the body's immune system attacks and destroys insulin-producing beta cells in the pancreas. Without insulin, people with T1D cannot regulate blood glucose levels effectively, leading to serious health complications. T1D affects an estimated 400,000 people in the UK alone, and tens of millions worldwide. Current treatment relies on insulin replacement through injections or pumps, but patients often face significant challenges including hypoglycaemia, long-term complications, and burdensome daily management.
The Bukhman Centre for Research Excellence in Type 1 Diabetes will bring together experts from across Oxford – including in medical sciences, chemistry, bioengineering and computer science - to drive collaborative, cross-disciplinary research. By leveraging Oxford's unique breadth and depth of expertise, alongside cutting-edge technology and infrastructure, the centre will serve as a catalyst for innovative breakthroughs that can be translated rapidly into life-changing advances for patients.
David Hodson, Professor of Diabetic Medicine at the Oxford Centre for Diabetes, Endocrinology and Metabolism in the Radcliffe Department of Medicine, said: 'With this generous gift, we will for the first time be able to bring a multidisciplinary research approach to bear on type 1 diabetes. Oxford's expertise in medical and physical sciences will allow us to make rapid and ground-breaking discoveries that will benefit individuals living with type 1 diabetes.'
Read the full story on the University of Oxford website.